676457-40-2

Usage

Structure

1H-1,2,4-Triazole-3-carboxylic acid, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-, methyl ester

Contains

Two chlorophenyl groups

Usage

Building block for the synthesis of pharmaceutical drugs with antifungal and antibacterial properties / Research reagent in chemical laboratories for the development of new drugs and compounds

Potential applications

Medicine, agriculture, and biotechnology.

Upstream product

• 91396-09-7 dimethyl [(4-chlorobenzoyl)amino]malonate 
• 554-00-7 2,4-Dichloroaniline 
• 104-88-1 4-chlorobenzaldehyde 
• 76862-09-4 methyl N-(4-chlorobenzylidene)glycinate 
• 74-11-3 para-chlorobenzoic acid 
• 122-01-0 4-chloro-benzoyl chloride 

Downstream Products

• 788156-72-9 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-1H-1,2,4-triazole-3-carboxamide 
• 676457-41-3 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,4-triazole-3-carboxylic acid 

Relevant academic research and scientific papers

Cycloaddition reactions of glycine imine anions to phenylazocarboxylic esters - A new access to 1,3,5-trisubstituted 1,2,4-triazoles

Phenylazocarboxylic tert-butyl esters have recently been shown to be highly versatile building blocks due to their ability to undergo nucleophilic aromatic substitutions under mild conditions, particularly well with [18F]fluoride, and to act as precursors for aryl radicals. In this article, we now report first examples for cycloaddition reactions to phenylazocarboxylates. In a one-pot reaction with readily accessible glycine imines, a variety of highly substituted 1,2,4-triazoles could be obtained.

Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds

The present invention relates to a novel medical use of compounds with CB1-receptor activity selected from the group of 4,5-dihydro-1H-pyrazole derivatives, 1H-Imidazole derivatives, thiazole derivatives and/or 1H-1,2,4-triazole-3-carboxamide d

NOVEL MEDICAL USES OF COMPOUNDS SHOWING CB1-ANTAGONISTIC ACTIVITY AND COMBINATION TREATMENT INVOLVING SAID COMPOUNDS

The present invention relates to a novel medical use of compounds with CB1--receptor activity selected from the group of 4,5-dihydro-1H-pyrazole derivatives, 1H-lmidazole derivatives, thiazole derivatives and/or 1H-1,2,4-triazole-3--carboxamide

Bioisosteric replacements of the pyrazole moiety of rimonabant: Synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists

Series of thiazoles, triazoles, and imidazoles were designed as bioisosteres, based on the 1,5-diarylpyrazole motif that is present in the potent CB1 receptor antagonist rimonabant (SR141716A, 1). A number of target compounds was synthesized an

1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID-CB1 RECEPTOR LIGANDS

The present invention relates to a group of 1H-1,2,4-triazole-3-carboxamide derivatives, to methods for the preparation of these compounds, and to pharmaceutical compositions containing at least one of these compounds as an active ingredient. These 1H-1,2

Potent imidazole and triazole CB1 receptor antagonists related to SR141716

Diarylimidazolecarboxamides and diaryltriazolecarboxamides related to SR141716 were synthesized and tested for binding to the human CB1 receptor. Suitably substituted imidazoles are comparably potent to the clinical candidate, whereas the analo